Upstate Active Clinical Trials

Study Title:

UTX-TGR-205 - A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 alone in Patients with Previously Treated Diffuse Large B-Cell Lymphoma

What is the purpose of the study?

This research study will evaluate the safety and efficacy of a study drug called TGR-1202 in combination with another study drug called ublituximab compared to TGR-1202 alone as a possible treatment for Diffuse Large B-cell Lymphoma (DLBCL) that has come back or that has not responded to standard treatment.

Upstate Institutional Review Board (IRB) Number:

916778

Study/Protocol ID:

UTX-TGR-205

Study Phase:

II

Patient Age Group:

Adults

Principal Investigator:

Teresa C Gentile, MD, PhD

ClinicalTrials.Gov ID:

NCT02793583

For more information about this trial go to ClinicalTrials.Gov

Who can I contact for more information?

Name: Deanna J Cogswell, LPN
Phone: 315-464-8237
Email: cogsweld@upstate.edu

Return to Previous Page || Search Again